Search & Analyze

CORONA Remedies Ltd.

2,166.90−48.15 (−2.17%)

BSE · 30 Oct, 4:01 PM

: ₹13,125.26 Cr
: 65.95
: 1,269
: ₹2,232.50 - ₹2,118.00
: ₹2,285.00 - ₹1,336.95

CORONA Remedies Ltd. (CORONA) share price closed at ₹2,166.90 on the BSE on Friday, October 30, 2026, down by 2.17% from its of ₹2,215.05. In that session CORONA reached a of 2,232.50 and of 2,118.00. The for the session was 2,175.99. The stands at 2,100.54 and is at 1,822.15. Looking at , the stock ended the session in Downtrend.

Stock Overview

₹2,218.05

₹2,215.05

₹2,175.99

₹2,100.54

Price 3.16% above

₹1,822.15

Price 18.92% above

Key Fundamentals

: 13,125.26 Cr₹13.13 Thousand Crore
: 32.54
: 65.95
: 16.27
: 131.94
: 328.55 Cr₹328.55 Crore
: 0.47 %
Sector
Industry: Pharmaceuticals & Drugs
: 27.36
: 0.19

Industry Comparison

Ratio	Company	Sector
	65.95	44.77
	0.19	0.20
	16.27	4.61
	0.97	1.81
	0.47 %	0.11 %
Operating Margin	21.27 %	19.15 %

Sector figures are the median of 154 listed Healthcare companies.

Peer Comparison

Name
SUN PHARMA. SUNPHARMA	1,778.25	38.91	4,26,661.74	0.90	1,995.07	-36.16%	16,198.71	11.88%	19.11
DIVI'S LAB. DIVISLAB	9,715.00	88.17	2,57,902.73	0.31	902.00	65.50%	3,080.00	27.80%	21.51
TORRENT PHAR TORNTPHARM	4,635.15	83.01	1,76,306.21	0.82	534.00	-9.64%	4,979.00	50.79%	19.27
LAURUSLABS LAURUSLABS	2,392.00	96.46	1,29,242.68	0.08	436.19	124.27%	2,206.37	33.44%	18.20
ZYDUSLIFE ZYDUSLIFE	1,244.00	27.50	1,24,089.48	0.08	990.20	-34.90%	8,017.00	21.96%	21.39
DR.REDDY'S DRREDDY	1,350.20	40.25	1,12,698.53	0.59	913.20	-31.69%	8,697.80	-1.48%	13.75
CIPLA LTD. CIPLA	1,380.00	38.48	1,11,488.55	0.94	851.51	-37.08%	7,403.93	-2.44%	16.00
CORONA Remedies Ltd. CORONA	2,166.90	65.95	13,125.26	0.47	60.11	30.11%	422.43	21.90%	31.74

Quarterly Results

consolidated figures in ₹ Crores · Quarterly

Particulars	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	313.87	297.69	293.69	346.54	361.13	342.42	353.09	422.43
Expenses	247.05	228.27	239.47	276.76	282.66	259.26	291.07	329.30
	66.82	69.42	54.22	69.78	78.47	83.16	62.02	93.13
	21.29%	23.32%	18.46%	20.14%	21.73%	24.29%	17.56%	22.05%
	2.46	0.76	1.42	2.02	2.27	-16.86	4.11	3.15
Interest	2.87	2.39	2.20	1.99	1.93	1.66	1.38	2.69
	9.05	9.69	10.04	8.92	9.20	9.45	10.29	13.24
	57.35	58.28	43.61	60.69	69.78	55.21	54.74	80.36
	25.07%	22.87%	27.65%	23.88%	25.02%	25.25%	17.19%	25.20%
	42.97	44.95	31.55	46.20	52.32	41.27	45.33	60.11
	7.03	7.35	5.16	7.55	8.55	6.75	7.41	9.83

Profit & Loss

consolidated figures in ₹ Crores · Annual

Particulars	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00
INCOME :
	898.23	1,037.09	1,175.11	1,379.41
	884.05	1,014.47	1,196.42	1,403.18
EXPENDITURE :
Increase/Decrease in Stock	-14.51	-0.78	-23.74	7.05
Raw Material Consumed	225.46	227.61	260.26	253.89
Power & Fuel Cost	3.97	5.66	6.03	5.69
Employee Cost	254.77	295.37	346.14	403.02
Other Manufacturing Expenses	9.24	12.24	15.34	27.11
General and Administration Expenses	166.53	187.63	215.68	265.63
Selling and Distribution Expenses	108.51	116.91	131.54	139.85
Miscellaneous Expenses	2.10	15.11	5.19	7.50
	756.07	859.74	956.44	1,109.74
Operating Profit (Excl OI)	127.98	154.73	239.98	293.44
	7.05	6.46	5.93	10.65
	135.03	161.19	245.91	304.09
Interest	4.27	14.44	10.60	6.97
PBDT	130.76	146.75	235.31	297.12
	20.10	28.28	37.16	37.87
Profit Before Taxation & Exceptional Items	110.66	118.48	198.15	259.25
Exceptional Income / Expenses				-19.10
	110.89	118.48	198.53	240.42
Provision for Tax	25.96	27.98	49.10	55.30
	84.93	90.50	149.43	185.12
Extra items			0.00	0.00
Consolidated Net Profit	84.93	90.50	149.43	185.12
Profit Balance B/F	228.27	305.78	377.67	503.60
Appropriations	313.20	396.28	527.10	688.72
Equity Dividend %	27.70%	37.00%	73.10%	100.00%
	13.89	14.80	24.43	30.27
Adjusted EPS	13.89	14.80	24.43	30.27

Balance Sheet

consolidated figures in ₹ Crores

Particulars	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
	61.16	61.16	61.16	61.16
Total Reserves	347.36	419.25	545.18	685.70
Reserve excluding Revaluation Reserve	347.36	419.25	545.18	685.70
Revaluation reserve	0.00	0.00
	408.52	480.41	606.34	746.86
Secured Loans		67.00	16.00
Deferred Tax Assets / Liabilities	-4.25	4.29	8.30	12.16
Other Long Term Liabilities	24.33	22.66	21.02	18.88
Long Term Provisions	24.81	32.03	38.61	66.07
Total Non-Current Liabilities	44.88	125.98	83.93	97.11
Trade Payables	94.37	114.30	143.52	147.07
Other Current Liabilities	18.39	50.43	51.66	45.82
Short Term Borrowings	2.33	31.14	10.70	126.86
Short Term Provisions	94.17	72.95	121.22	134.78
Total Current Liabilities	209.26	268.81	327.10	454.53
Total Liabilities	662.66	875.20	1,017.37	1,298.50
Gross Block	256.34	483.05	502.58	723.59
Less: Accumulated Depreciation	71.75	99.35	132.70	169.62
	184.59	383.70	369.88	553.97
	64.71	120.59	185.95	143.12
Non Current Investments	25.53	25.55	25.96	26.29
Long Term Investment	25.53	25.55	25.96	26.29
Long Term Loans & Advances	9.54	8.56	9.10	4.75
Other Non Current Assets	14.91	2.27	0.10	128.70
Total Non-Current Assets	299.28	540.66	590.99	856.83
Currents Investments	5.97
Inventories	105.40	98.35	129.48	125.00
Sundry Debtors	86.99	99.93	118.29	145.55
Cash and Bank	76.70	69.90	69.27	44.12
Other Current Assets	3.03	3.79	6.89	2.28
Short Term Loans and Advances	85.30	62.57	102.45	124.72
Total Current Assets	363.38	334.54	426.38	441.67
Net Current Assets (Including Current Investments)	154.12	65.72	99.28	-12.86
Total Assets	662.66	875.20	1,017.37	1,298.50
				1.01
Total Debt	2.33	134.14	62.70	142.86
	66.80	78.55	99.14	122.12
Adjusted Book Value	66.80	78.55	99.14	122.12

Cash Flow

consolidated figures in ₹ Crores

Particulars	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00
	110.89	118.48	198.53	240.42
Adjustment	22.55	46.87	52.31	44.35
Changes In working Capital	-4.92	9.32	-17.07	-5.87
Cash Flow after changes in Working Capital	128.52	174.66	233.77	278.90
Cash Flow from Operating Activities	102.70	156.76	190.49	229.48
Cash Flow from Investing Activities	-50.25	-266.64	-83.86	-256.15
Cash Flow from Financing Activitie	-44.75	98.55	-106.57	25.28
Net Cash Inflow / Outflow	7.71	-11.34	0.06	-1.39
Opening Cash & Cash Equivalents	6.82	14.49	3.16	3.22
Effect of Foreign Exchange Fluctuations	-0.04	0.00
Closing Cash & Cash Equivalent	14.49	3.16	3.22	1.83

Ratios

Valuation

65.95

16.27

40.25

8.87

32.54

131.94

Profitability

27.36

31.74

15.99

21.27

13.42

Leverage & Liquidity

0.19

0.97

35.49

Returns

0.47

1.19

Shareholding Pattern

Numbers in percentages

Particulars	Dec '25	Mar '26	Jun '26	Sep '26
	69.00	69.00	69.00	69.00
	8.60	9.27	16.53	20.66
	22.40	21.74	14.48	10.34
	31.00	31.00	31.00	31.00
No. of Shareholders	31,035	19,609	20,185	21,098

Mutual Funds Invested(42)

Based on each fund's latest monthly portfolio · Sep 2026

A total of 39 active funds hold 16.08% in CORONA Remedies Ltd., contributing to ₹2.06K Cr of holdings

Fund				As of
HD HDFC Flexi Cap Fund - Growth - Direct PlanFlexi Cap Fund	488.46	0.45	23,33,333	Sep '26
IN Invesco India Smallcap Fund - Growth - Direct PlanSmall cap Fund	293.55	1.82	14,02,282	Sep '26
SB SBI Dividend Yield Fund - Growth - Direct PlanEquity - Dividend Yield Fund	180.03	2.23	8,60,000	Sep '26
IN Invesco India Midcap Fund - Growth - Direct PlanMid Cap Fund	146.54	0.93	7,00,000	Sep '26
SB SBI Healthcare Opportunities Fund - Growth - Direct PlanPharma & Health Care	142.35	2.43	6,80,000	Sep '26
IN Invesco India Large & Mid Cap Fund - Growth - Direct PlanLarge & Mid Cap	112.88	0.93	5,39,225	Sep '26
AB Aditya Birla Sun Life ELSS Tax Saver Fund - Growth - Direct PlanEquity - ELSS - Tax Saver Fund	96.72	0.71	4,62,035	Sep '26
SB SBI Retirement Benefit Fund - Aggressive Plan - Growth - Direct PlanEquity Oriented	63.38	2.07	3,02,752	Sep '26
UN Union Small Cap Fund - Growth - Direct PlanSmall cap Fund	60.10	2.20	2,87,095	Sep '26
IN Invesco India Multicap Fund - Growth - Direct PlanMulti Cap Fund	59.64	1.39	2,84,887	Sep '26

Corporate Actions

Showing: All

Date	Type	Details
2026-10-16	Board Meeting	Quarterly Results
2026-07-17	Board Meeting	Quarterly Results
2026-06-16	AGM

Insider Trading

Date	Person	Category	Transaction Type	Shares
2026-08-19	Apurvsinh Kirtisinh Parmar	Market	Buy	50
2026-08-19	Apurvsinh Kirtisinh Parmar	Market	Buy	50
2026-08-19	Apurvsinh Kirtisinh Parmar	Market	Buy	50
2026-08-19	Kirtisinh Manoharsinh Parmar	Market	Buy	50
2026-08-19	Kirtisinh Manoharsinh Parmar	Market	Buy	50
2026-08-19	Kirtisinh Manoharsinh Parmar	Market	Buy	35
2026-08-19	Kirtisinh Manoharsinh Parmar	Market	Buy	6
2026-08-19	Kirtisinh Manoharsinh Parmar	Market	Buy	48
2026-08-19	Kirtisinh Manoharsinh Parmar	Market	Buy	1
2026-08-19	Kirtisinh Manoharsinh Parmar	Market	Buy	50
2026-08-19	Kirtisinh Manoharsinh Parmar	Market	Buy	2
2026-08-19	Kirtisinh Manoharsinh Parmar	Market	Buy	43
2026-08-19	Ranjanben Kirtisinh Parmar	Market	Buy	90
2026-08-19	Ranjanben Kirtisinh Parmar	Market	Buy	75

Sector Overview

HealthcarePharmaceuticals & Drugs

CORONA Remedies Ltd. operates in the Healthcare sector under the Pharmaceuticals & Drugs industry. This sector is one of the key drivers of the Indian economy and is closely tracked by the relevant Nifty sectoral index.

Company Profile

Corporate information and contact details

Key Management

18 members across the board and senior leadership

Chetna Dharajiya

Company Secretary & Compliance Officer

—

Kirtikumar Laxmidas Mehta

Chairman

₹1.00 Cr

Mar '25

Kirti Mehta

Chairman

₹1.00 Cr

Mar '26

Niravkumar Kirtikumar Mehta

Managing Director & Chief Executive Officer

₹4.00 Cr

Mar '25

Nirav Mehta

Managing Director & Chief Executive Officer

₹4.00 Cr

Mar '26

Ankur Kirtikumar Mehta

Joint Managing Director

₹4.00 Cr

Mar '25

Ankur Mehta

Joint Managing Director

₹4.00 Cr

Mar '26

Viral Bhupendrabhai Sitwala

Whole Time Director

₹90.60 L

Mar '25

Ameet Desai

Non Executive Independent Director

₹3.00 L

Mar '26

Ameetkumar Hiranyakumar Desai

Non Executive Independent Director

₹60.00 L

Mar '25

Monica Kanuga

Non Executive Independent Director

₹3.00 L

Mar '26

Monica Hemal Kanuga

Non Executive Independent Director

₹1.50 L

Mar '25

Bhaskar Iyer

Non Executive Independent Director

₹3.00 L

Mar '26

Shirish Gundopant Belapure

Non Executive Independent Director

₹80,000

Mar '25

Viral Sitwala

Whole Time Director

₹1.08 Cr

Mar '26

Bhaskar Vemban Iyer

Non Executive Independent Director

₹80,000

Mar '25

Shirish Belapure

Non Executive Independent Director

₹3.00 L

Mar '26

Chetna Prabhatkumar Dharajiya

Company Secretary & Compliance Officer

—

CORONA Latest News

News

10 of 10 articles

EQUITY23 Oct 2026 · 09:44

CORONA Remedies moves up on BSE

The company had secured GMP certification from Brazilian Health Regulatory Agency

EQUITY22 Oct 2026 · 15:03

CORONA Remedies rises on getting GMP certification from Brazilian Health Regulatory Agency

The GMP compliance certification is for its OSD manufacturing facility and Hormone manufacturing facility, both located at Bhayla, Ahmedabad

COMPANY22 Oct 2026 · 14:58

CORONA Remedies gets GMP certification from Brazilian Health Regulatory Agency

The GMP compliance certification is for its OSD manufacturing facility and Hormone manufacturing facility, both located at Bhayla, Ahmedabad

EQUITY18 Sept 2026 · 15:59

Corona Remedies informs about analyst meet

EQUITY10 Aug 2026 · 15:55

Corona Remedies informs about analyst meet

EQUITY10 Jul 2026 · 10:28

Corona Remedies informs about AGM proceedings

EQUITY6 Jul 2026 · 17:06

Corona Remedies informs about compliances-certificate

EQUITY19 Jun 2026 · 15:55

Corona Remedies informs about updates

EQUITY19 Jun 2026 · 14:56

Corona Remedies informs about disclosure

EQUITY19 Jun 2026 · 14:31

Corona Remedies informs about disclosure

CORONA Remedies Ltd.

Stock Overview

Price chart

Peer Comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flow

Ratios

Valuation

Profitability

Leverage & Liquidity

Returns

Shareholding Pattern

Mutual Funds Invested(42)

Corporate Actions

Insider Trading

Sector Overview

Company Profile

Key Management

CORONA Latest News

News